About Contact Us Careers
Sign In

Acute Disseminated Demyelination Treatment Market Size & Share, by Treatment Type {Corticosteroids, Immunoglobulin IVIg Therapy, Plasmapheresis }; End-user (Hospitals, Clinics, Ambulatory Surgical Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4933
  • Published Date: May 03, 2023
  • Report Format: PDF, PPT

Companies Dominating the Acute Disseminated Demyelination Treatment Landscape

top-features-companies
    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Johnson & Johnson Service, Inc.
    • Novartis AG
    • Merck & Co. GmbH
    • F. Hoffman-La Roche AG
    • Sanofi SA
    • Bayer AG
    • GlaxoSmithKline plc
    • Abbott Laboratories
    • Amgen, Inc.
Browse Key Market Insights with Data Illustration:

In the News

  • The European Union has authorized Biogen Inc.'s medication Tysabri (natalizumab) for the treatment of acute diffuse demyelination. A monoclonal antibody called Tysabri, which targets immune cells, is intended to lessen the inflammation brought on by acute disseminated demyelination.
  • The European Union has approved Novartis International AG's medication Kesimpta (ofatumumab) for the treatment of acute disseminated demyelination. Kesimpta is a monoclonal antibody that is injected under the skin and targets immune cells.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4933
  • Published Date: May 03, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the market growth are the increasing prevalence of autoimmune diseases across the globe and the rising number of cases of acute disseminated demyelination.

The market size of acute disseminated demyelination treatment is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2023-2035.

Poor health infrastructure in underdeveloped nations is estimated to hamper market growth.

North America is estimated to create notable growth opportunities for market growth over the forecast period.

The major players in the market are Pfizer, Inc., Johnson & Johnson Service, Inc., Novartis AG, Merck & Co. GmbH, and Others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment, end user, and region.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying